Table 3.

Multivariate models. Stepwise optimization in A) the Knight-ADRC study, and B) the ADNI study. C) A minimal model that includes the analytes commonly selected in A and B.

A)	Inferred Knight-ADRC Model		Replication on ADNI
	p-value	effect	p-value	effect
H-FABP	3.18E-08	0.44	1.74E-11	0.47
VEGF	1.01E-05	−0.63	1.85E-04	−0.66
TNF.RII	8.56E-04	0.63	1.08E-01	0.22
Thrombomodulin	2.03E-03	−0.37	1.01E-03	−0.39
ACE	2.25E-03	−0.36	8.66E-01	−0.02
Adiponectin	2.29E-03	0.17	7.98E-03	0.23
HGF	2.69E-03	0.51	5.60E-08	0.60
MIF	3.30E-03	0.33	5.88E-04	0.16
SAP	4.26E-03	−0.21	9.67E-01	0.00
CXCL9	8.17E-03	−0.14	9.23E-01	−0.01
FasL	1.12E-02	0.21	2.95E-01	−0.10
age	1.33E-01	0.01	3.17E-01	−0.01
sex	4.84E-01	−0.05	3.57E-01	−0.07
APOE Genotypes	2.80E-07	0.14	3.64E-11	0.19
R squared/BIC	0.50/−323.91		0.56/−222.42.68

B)	Replication on Knight-ADRC		Inferred ADNI Model
	p-value	effect	p-value	effect
H-FABP	2.50E-09	0.44	5.06E-16	0.50
HGF	2.39E-02	0.37	2.19E-11	0.68
VEGF	1.65E-04	−0.60	4.99E-06	−0.68
Complement 3	7.57E-01	−0.03	2.62E-05	−0.63
ANGPT2	4.04E-01	0.12	2.10E-04	0.41
APOA	1.13E-02	−0.26	2.58E-04	0.39
MIF	2.08E-02	0.33	6.71E-04	0.14
Fibrinogen	2.02E-01	0.09	1.73E-03	−0.12
Prolactin	6.80E-01	−0.04	9.88E-03	−0.26
TRAIL.R3	8.13E-01	0.04	1.70E-02	−0.28
sex	4.96E-01	0.05	8.60E-01	−0.01
age	7.24E-03	0.01	9.89E-01	0.00
APOE Genotypes	7.90E-08	0.16	6.16E-17	0.22
R squared/BIC	0.44/−296.91		0.60/−370.60

C)	Knight-ADRC		ADNI
	p-value	effect	p-value	effect
H-FABP	6.44E-10	0.45	1.87E-14	0.50
HGF	3.25E-02	0.33	5.93E-09	0.51
MIF	6.27E-04	0.40	3.11E-04	0.16
VEGF	3.47E-05	−0.59	1.32E-06	−0.66
age	6.78E-03	0.01	3.51E-01	0.00
sex	3.27E-01	0.06	9.73E-01	0.00
APOE Genotypes	9.46E-09	0.16	1.44E-14	0.21
R squared/BIC	0.42/−336.92		0.53/−360.04